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Introduction: Stem cell therapy has emerged as potential therapeutic strategy for damaged heart muscles.
Umbilical cord blood (UCB) cells are the most prevalent stem cell source available, yet have not been fully tested in
cardiac regeneration. Herein, studies were performed to evaluate the cardiovascular safety and beneficial effect of
mononuclear cells (MNCs) isolated from human umbilical cord blood upon intramyocardial delivery in a murine
model of right ventricle (RV) heart failure due to pressure overload.
Methods: UCB-derived MNCs were delivered into the myocardium of a diseased RV cardiac model. Pulmonary
artery banding (PAB) was used to produce pressure overload in athymic nude mice that were then injected
intramyocardially with UCB-MNCs (0.4 × 10^6 cells/heart). Cardiac functions were then monitored by telemetry,
echocardiography, magnetic resonance imaging (MRI) and pathologic analysis of heart samples to determine the
ability for cell-based repair.
Results: The cardio-toxicity studies provided evidence that UCB cell transplantation has a safe therapeutic window
between 0.4 to 0.8 million cells/heart without altering QT or ST-segments or the morphology of electrocardiograph
waves. The PAB cohort demonstrated significant changes in RV chamber dilation and functional defects consistent
with severe pressure overload. Using cardiac MRI analysis, UCB-MNC transplantation in the setting of PAB demonstrated
an improvement in RV structure and function in this surgical mouse model. The RV volume load in PAB-only mice
was 24.09 ± 3.9 compared to 11.05 ± 2.09 in the cell group (mm3, P-value <0.005). The analysis of pathogenic gene
expression (BNP, ANP, Acta1, Myh7) in the cell-transplanted group showed a significant reversal with respect to the
diseased PAB mice with a robust increase in cardiac progenitor gene expression such as GATA4, Kdr, Mef2c and
Nkx2.5. Histological analysis indicated significant fibrosis in the RV in response to PAB that was reduced following
UCB-MNC’s transplantation along with concomitant increased Ki-67 expression and CD31 positive vessels as a
marker of angiogenesis within the myocardium.
Conclusions: These findings indicate that human UCB-derived MNCs promote an adaptive regenerative response
in the right ventricle upon intramyocardial transplantation in the setting of chronic pressure overload heart failure.* Correspondence: nelson.timothy@mayo.edu
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Cell-based therapy has emerged as a potential therapeutic
strategy for restoring damaged cardiac tissue with a focus
on left ventricular function. There is a spectrum of cell
types utilized for cardiac applications including bone
marrow-derived mononuclear cells (MNCs) or mesenchy-
mal stromal cells (MSCs) with newer protocols isolating or
guiding the expansion of specific subpopulations [1]. Cell-
based therapy has offered promising evidence with mixed
results that suggest an unharnessed potential for cell ther-
apy that may be tailored for individual needs to impede
progressive heart failure [2-4]. Human umbilical cord
blood (h-UCB) stem cells have generated significant atten-
tion in regenerative medicine with recent studies demon-
strating the ability of UCB derived cells to differentiate
into various cell types [5,6]. Preclinical studies with UCB
cells have demonstrated their efficacy in various diseases,
such as heatstroke, amyotrophic lateral sclerosis, post-
infarct cardiac regeneration, and liver diseases [4,7-11].
Subsequently, multiple groups have demonstrated that the
delivery of UCB cells has the potential to improve cardiac
function in animals following acute myocardial infarction
(MI) in the left ventricle [12-14]. Recent studies in a novel
sheep model of chronic right ventricular volume overload
showed that UCB cells transplanted in the right ventricle
improved heart function [15]. These studies demonstrated
that UCB stem cells are multipotent and capable of differ-
entiating into non-blood cell types [16]. These observa-
tions raised the possibility of using autologous UCB cells
in congenital disease to repair ventricular myopathy. Fur-
thermore, some of the most refractory forms of congenital
heart disease are the result of dysfunctional systemic right
ventricle failing in response to chronic pressure overload
[17]. Therefore, determining the safe dosing and delivery
strategy of UCB-derived cells to promote endogenous re-
generative capacity within the right ventricle becomes a
critical opportunity for regenerative medicine.
The current studies reported herein were performed to
evaluate the cardiovascular safety and efficacy profile of h-
UCB-derived MNCs received via intramyocardial delivery
into the right ventricle of a pressure overloaded murine
model. The murine model with pulmonary artery banding
(PAB) restricts the blood flow and causes right ventricular
dysfunction due to pressure overload and increased vol-
ume of the right ventricle. The present findings indicate
that UCB-MNCs may have the capacity to repair the dam-
aged cardiac tissue and will launch further investigations
to determine whether UCB-MNC therapy could be used
to treat right ventricular heart failure.
Methods
Ethical approval
All animal experiments were approved by the ‘Institu-
tional Animal Care and Use Committee’ (IACUC-ProtocolA45410), Comparative Medicine, at Mayo Clinic. The ex-
perimental animals received care in compliance with the
‘Guide for the Care and Use of Laboratory Animals’. In
addition, all experiments were carried out in compliance
with the Helsinki Declaration. h-UCB-derived MNCs were
isolated from cord blood of normal donors with informed
consent according to the institutional guidelines under the
approved protocol. The cord blood was collected and proc-
essed at Mayo Clinic with the approval of the ‘Mayo Clinic
Institutional Review Board’ (IRB protocol- 11–002535) and
manufactured to mononuclear cells according to our good
manufacturing practice (GMP) process in the Human Cell
Therapy Laboratory, Mayo Clinic, Rochester, MN.
Experimental design
Athymic nude mice at six- to eight-weeks of age were
purchased from Harlan Laboratories (Indianapolis, IN,
USA). All the animals were housed at the Mayo Clinic
animal house facility and maintained under temperature
and humidity according to the the guidelines. Mice were
housed individually after surgery in polypropylene cages
and were allowed water and pelleted food ad libitum.
Human cord blood was collected from the umbilical
cord vein and the mononuclear fraction was isolated
from the cord blood by density gradient centrifugation.
Subsequently, the obtained cell population was rapidly
frozen in CryoStor freezing media, pre-formulated with
10% dimethyl sulfoxide (DMSO). Prior to cell transplant-
ation in the murine heart, the UCB cells were thawed
and evaluated for viability.
Cardiac safety evaluations
Athymic nude mice were randomly divided into four
groups. Prior to telemetry implantation in mice, the base-
lines of body weight, electrocardiogram (ECG), heart rate,
and temperature were monitored (Figure 1A). Subse-
quently, UCB-MNCs were transplanted in the myocar-
dium of the right ventricle. Cardiovascular safety
parameters were monitored for three weeks after cell
transplant and the animals were then sacrificed for gross
and histopathology.
Surgical procedure for DSI transmitter implantation
Animals were subcutaneously implanted with a telem-
etry device (PhysioTel and TA ETA-10, Data Science
International, St. Paul, MN, USA) for remote and long-
term monitoring of physiological and bioelectrical vari-
ables (for example, blood pressure, heart rate, ECG) in
conscious, unrestrained animals. On the day of the ex-
periment, the animals were weighed and anesthetized
for telemetry transmitter implantation according to the ani-
mal protocol approved by IACUC (Institutional Animal
Care and Use Committee). During surgery, animals were
maintained in a surgical plane of anesthesia, on a heating
Figure 1 Study design. (A) Safety studies: the primary focus of the study was to investigate potential adverse cardiovascular effects of umbilical
cord blood mononuclear cells transplantation in the right ventricle of mouse heart. A dose escalation study was carried out to assess the possible
side effects and estimate the dosage likely to be the safety margin of UCB-MNCs. (B) Efficacy studies: the second part of the study was designed
to explore the possible beneficial effects involved in right ventricular remodeling upon intramyocardial injection of UCB cells in a disease model
with pressure overload right heart failure. MNCs, mononuclear cells; UCB, umbilical cord blood.
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telemetric transmitter devise was implanted in the ventral
abdominal area subcutaneously under isoflurane anesthesia.
The paired wire electrodes (negative and positive leads)
were placed under the skin of the thorax. The skin incision
was closed by sutures and animals were used for cell trans-
plantation three to seven days after surgery.
Telemetry data acquisition and recording
ECG and temperature were recorded continuously for
three hours prior to UCB cell injections with DSI data
acquisition software. The ECG was monitored for three
hours continuously after cell injection. The ECG,
temperature and other parameters such as body weight
were recorded every three days up to three weeks. The
ECG waveform was displayed and recorded by Data-
quest software and analyzed to determine time latency
for QT intervals and heart rate changes by DSI Pone-
mah software.
Umbilical cord blood-derived MNCs transplantation to the
right ventricle
Mice were anesthetized in a closed chamber filled with
oxygen and 2% to 3% isoflurane. The chest was shavedand mice were placed on a heating pad at a temperature
of 37°C. The mice were intubated with a 20G needle
catheter and mechanically ventilated with a Harvard
mini-ventilator (model 687, Hugo Sacks, Elektronik,
Germany) at a rate of 180 breaths per min and a tidal
volume of 125 μl. Following ventilation, an incision was
made through the 4th and 5th right intercostal space to
expose the epicardium of the right heart. The cell treated
groups of mice received an intramyocardial injection (0.2,
0.4 or 0.8 × 106 cells/mouse) to the right ventricle (five in-
jections of 2.5 μl each) by using a syringe pump 11 elite
(Harvard Apparatus, Holliston, MA, USA).Echocardiography
Three weeks following cell transplantation, right/left
ventricular function and structures, and the absence of
adverse effects, including uncontrolled growth were pro-
spectively evaluated by echocardiography (Vevo2100
with a MS-400 30-MHz transducer, Visual Sonics,
Toronto, Canada). The animals were sedated with isoflur-
ane inhalation (2%) and long and short axis views were
obtained with both M-mode and two-dimensional echo
images.
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Right ventricular pressure overload via pulmonary artery
banding
Athymic nude mice six- to eight-weeks of age under-
went pulmonary artery banding (Figure 1B). A left lateral
thoracotomy was performed through the 2nd intercostal
space and exposed the heart [18]. After mobilization of
the pericardium, the pulmonary trunk was bluntly dis-
sected with a curved fine forceps from the aorta and left
atrium. A tunnel was created underneath the pulmonary
trunk using an L-shaped 28 gauge blunted needle. Fol-
lowing this procedure, a 7–0 surgical suture was placed
around the pulmonary artery and tied over a 25G needle
bent into an L-shape. The L-shaped needle was removed
immediately to leave a consistent ligature around the
pulmonary artery. The chest cavity was closed layer by
layer. As the growth of the animals increases, the fixed
diameter ligature results in a pressure overload in the
right ventricle. Mice that did not receive any treatment
(that is, surgery and cells) served as controls.
Pulmonary artery banding and cell implantation into
right ventricular myocardium
Four weeks after PAB and model validation, another thora-
cotomy was performed as previously described for the pur-
pose of delivering the cells directly into the epicardium of
the right ventricle. The UCB-MNCs (0.4 million cells/heart)
were injected into four or five sites of the right ventricle as
previously described with each injection being no more
than 2.5 μl.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) was per-
formed both four weeks after PAB and four weeks after
cell transplantation by magnetic cardiac imaging (16.4 T
Bruker ultrashield 700WB plus scanner, Bruker BioSpin
Corporation, Billerica, MA, USA). The cardiac MRI per-
formed prior to PAB was considered a control (basal)
recording, followed by banding (after four weeks) and
then cell transplantation with another four weeks of
monitoring. The mice were anesthetized and placed in a
cone shaped chamber connected to a ventilator for the en-
tirety of the scanning procedure. The scan was adjusted by
heart position and by different modes of scan, such as
transversal, coronal and sagittal [19]. The scanning was
done in short axis and a stack of seven 1 mm slices was
measured in the base area of the right ventricle (RV). The
acquired MRI data were analyzed with digital imaging soft-
ware (‘Analyze,’ Biomedical Imaging Resource, BIR, Mayo
Clinic, Rochester, MN, USA). Each DICOM series was
loaded into a three-dimensional volume. Thresholding
was used in each image of the dataset to segment the
blood pool, with contrast, in the atria. Voxel counting and
voxel dimensions were used to determine the volume.Real-time PCR analyses
Real-time RT-PCR analysis was carried out using RNA
isolated from the heart tissue (free wall RV) using an
RNeasy Plus Mini kit (Qiagen, Valencia, CA, USA). The
reverse transcriptase (RT) reaction was performed using
an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA). Quantitative assessment of predictive cardiac
markers, ANP, BNP, Acta-1, Myh7, Myh6, and cardiac
progenitor markers, GATA-4, Kdr, Mef2c and Nkx2.5,
was performed by real-time PCR. The target values were
normalized to GAPDH and are expressed as 2−ΔΔCt (fold
difference).Immunofluorescence
The expression of Ki-67 and CD31 staining for blood
vessel formation was determined in PAB and cell treated
ventricles by immunofluorescence staining and observed
via confocal microscopy. The primary antibodies used
for the immunolabeling studies were rabbit polyclonal to
Ki-67 and CD31 (Abcam, Cambridge, MA, USA), fixed
paraffin sections at 1:200 for identification of Ki-67 posi-
tive cells and endothelial cells, respectively. The samples
were then incubated with the secondary antibody, anti-
mouse FITC-conjugated, for one hour. The immuno-
fluorescence staining was acquired with a Zeiss LSM
510 confocal microscope. The quantification of Ki-67
and CD31-positive blood vessels was done by CellSens
Dimension software.Tissue collection and histopathology
Hearts were harvested from control and experimental
groups of animals at four and eight weeks after cell trans-
plantation. For histological examination, hearts were fixed
in 10% neutral formalin and embedded into paraffin by
standard techniques. After serial sectioning of hearts (apex
to base), 5-micron sections were stained with hematoxylin
and eosin (H & E) and Masson Trichrome stain for patho-
logical observations. H & E sections were examined by
light microscopy for any tumor formation and fibrotic
areas were observed by analysis of Masson Trichrome
stained sections. The heart tissue was excised and the free
walls of the RV and left ventricle (LV) were separated and
stored in −80°C for RNA isolation.Statistical analysis
Data are presented as mean ± SE of the mean of at least
four independent experiments. Statistical analysis was
performed using Graph Pad Prism 5 (La Jolla, CA, USA)
software. The differences between the groups were evalu-
ated by unpaired one-way analysis of variance (ANOVA)
test and differences were considered significant when a
P-value <0.05.
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Safety of intramyocardial transplantation of umbilical
cord blood-derived mononuclear cells in the right
ventricle
In vivo cardiovascular tolerance studies using three
doses (lower, mid and higher) of UCB-MNCs adminis-
tered into the myocardium of normal mice demon-
strated the safety dose for the RV. Animal body weights
were monitored before and after cell injections. There
was no weight loss within three weeks of cell transplant-
ation (Figure 2A). Furthermore, body temperature was
used as a marker of overall health of the animal and anyFigure 2 Lack of evidence for ventricular arrhythmias and QT interval prolo
0.8 million cells) of UCB-MNCs were transplanted on the right ventricle to e
temperatures measured up to three weeks followed by UCB-MNCs transpla
conscious animals (C). Data presented as means ± SE. (D) ECG tracing from
transmitter recorded at baseline and 3, 6, 9, 12, 15, 18 and 21 days after int
blood-mononuclear cells.allergic or infectious side effects and was monitored
daily following the cell transplantation. Following injection
of UCB cells, a decrease in body temperature was noticed
on day 1; however, by three to five hours post-surgery the
body temperature returned to normal (Figure 2B). Telem-
etry devices were implanted and recorded the baselines of
HR and ECG prior to cell delivery. The UCB-MNCs were
then transplanted and animals were followed for three
additional weeks. The telemetry implantation, cell trans-
plantation, and recovery periods were well tolerated in all
mice upon standardization of each protocol. The data re-
cordings were generated for three hours at each timengation after UCB-MNCs transplantation. Multiple doses (0.2, 0.4 and
valuate cardiac safety and tolerability (n = 7). (A, B) Body weights and
ntation. Heart rate (HR) was derived from telemetric recording in
a conscious mouse implanted subcutaneously with a telemetry
ramyocardial injection of UCB-MNCs. UCB-MNCs, umbilical cord
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mouse baseline HR prior to cell injection is approximately
600 to 700 beats/minute (Figure 2C). A lower HR was ob-
served on day 1 due to surgical manipulation, but there-
after there was no significant difference in heart rates
between control and cell transplanted groups from base-
line recordings. Furthermore, UCB-MNCs did not alter
the QT-segments or the morphology of ECG waves after
cell transplantation at doses of 0.2, 0.4 or 0.8 million cells/
mouse (Figure 2D). The doses used here demonstrated an
acceptable safety margin for h-UCB cells to be adminis-
tered intramyocardially.Figure 3 No detectable risk of cardiovascular toxicity from UCB-MNCs deliv
images three weeks after UCB-MNC transplantation indicating normal card
comparison (0.2 million (low dose) to 0.8 million cells (high dose)) of echoc
sections stained with hematoxylin & eosin (H & E) three weeks after RV my
injection. Higher magnification images were captured at x100. UCB-MNC tr
of tumor formation upon histological examination in any animals. (C) Hear
injection of UCB-MNCs. The average ratio of fibrosis area per RV area was m
right ventricle; UCB-MNCs, umbilical cord blood-mononuclear cells.Ventricular structure and function following
intramyocardial delivery of UCB-MNCs
Low to high doses of UCB-MNCs delivered to the RV
were followed by echocardiography after three weeks of
cell transplantation. Structure and function was equiva-
lent between controls and mice administered UCB-
derived MNCs at all doses. Notably, echocardiography
showed normal left and right ventricular size/function
and no tumor mass was observed (Figure 3A). The data
demonstrated normal sinus rhythm and showed no evi-
dence of any tumor or abnormal mass effect in control
or cell treated groups of animals. The left ventricularered into the myocardium of the right ventricle. (A) Echocardiographic
iac function and no signs of tumor formation in any of the doses. A
ardiography was performed in this study. (B) Histo-pathological
ocardial injection. Short-axis sections were used to identify the area of
ansplantations showed no incidence of lesion in the RV and no signs
t sections stained with Masson Trichrome stain (blue) after myocardial
easured to determine the fibrotic area. N = 4, Scale bars = 200 μm. RV,
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Three weeks of follow-up study reflected no significant
difference in diastolic and systolic volume within both
groups of animals. Cardiac tissue of both control and
cell transplanted mice was harvested three weeks after
cell delivery for histological evaluation. Myocardial tissue
was stained with H & E and examined for any tumor
formation. Histological data evaluated by light microscopy
did not show any evidence of lesions or tumor growth in
the experimental group or control group (Figure 3B).
Masson Trichrome staining did not reveal any fibrotic
area in either group of animals (Figure 3C). Overall, the
cardio-toxicity studies provided evidence that cell trans-
plantation has a safe therapeutic window between 0.4 and
0.8 × 106 cells/heart. This data demonstrated no detect-
able risk for cardiovascular toxicity of UCB-MNCs deliv-
ered into the myocardium of the right ventricle.Figure 4 Chronic pressure overload results in morphological and functiona
banding, UCB-MNCs were transplanted into the right ventricle. Body weigh
eight weeks (A, B). There was no significant difference in weight gain betw
animals in each group. (C) Wet weight of whole heart was recorded eight
between cell transplanted and PAB-only groups. A trend towards increase
P >0.5). (D) The PAB model was validated prior to cell delivery. After PAB, the
tract stenosis resulting in right ventricular dilation (E). PAB, pulmonary artery bEfficacy of UCB-derived MNCs transplanted into chronic
RV pressure overload
Evaluation of structural changes in the pressure overloaded
right heart
A surgical PAB model with severe RV pressure and in-
creased volume was created in immunodeficient mice to
allow for safety and efficacy studies of h-UCB-derived cells.
The average body weight and temperature was marginally
decreased between one and two weeks of surgery; however,
there was no significant difference in weight gain after four
and eight weeks of follow-up (Figure 4A). Significant
changes in the body temperature observed between one
and four week after surgery (Figure 4B). MNCs administra-
tion in the RV showed a marginal increase in heart wet
weight; however, the PAB only group did not show any sig-
nificant increase in heart weight at eight weeks of the study
period (Figure 4C). Mice with a pressure overloaded RVl changes in the right ventricle. Four weeks after pulmonary artery
ts and temperatures were recorded at baseline and two, four, six and
een the control, PAB-only and PAB + cells groups. The data depict six
weeks after pulmonary artery banding. A comparison was made
in heart weight was observed in the cell transplanted group (n = 6;
right ventricle is exposed to pressure overload by pulmonary outflow
anding; UCB-MNCs, umbilical cord blood-mononuclear cells.
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an increased volume in the right ventricular chamber
(Figure 4 D, E).
UCB-derived MNC therapy on right ventricular remodeling
after chronic right ventricular pressure overload
The second aim of the study was to examine whether
UCB-derived MNC injection in the pressure overloaded
RV would enhance cardiac function compared to the
PAB-only. After the PAB model validation by MRI, 0.4
million cells were injected into the right ventricular
myocardium to measure the recovery of RV function.
Average body weight and temperature throughout the
eight-week period of study indicated a marginal weight
gain in the cell treated group of animals (Figure 4 A, B).
After four weeks of cell treatment, MRI was used to
monitor changes in cardiac function and structure. The
baseline MRI studies were performed prior to PAB sur-
gery. The dysfunctional RV model was validated in MRI
studies prior to UCB-MNCs delivery. Pulmonary artery
constriction caused a failing heart phenotype including
RV chamber dilation and right ventricular dysfunctionFigure 5 Myocardial delivery of UCB-MNCs improves RV function and favo
image obtained from magnetic resonance imaging in the three experimen
dilation and ventricular dysfunction when compared with control (sham) a
less-pronounced RV dilation in the UCB-MNCs transplanted group (n = 6). (
control, PAB and cell transplanted group. The PAB only group demonstr
Intramyocardial delivery of UCB-MNCs indicated a reduction in RV volum
was compared among groups; the PAB-only animals showed a significan
transplanted group demonstrated a smaller reduction of the RV wall thi
between the experimental groups. LV, left ventricle; PAB, pulmonary arte
blood-mononuclear cells.(Figure 5A). Four weeks after PAB, a severe RV dilation
was noticed in all animals (Figure 5-top panel). Four
weeks after UCB-MNCs injection, MRI revealed a reco-
very of right ventricular chamber size and volume. The
right ventricular volumes were measured from multi-
section images (ventricular short axis). The RV volume
loading PAB mice was 24.09 ± 3.9 compared to 11.05 ±
2.09 in the cell treated group (mm3; P = 0.005) (Figure 5B).
Imaging analysis showed an increase in wall thickness and
reduced RV chamber size in the cell treated group com-
pared to PAB only experiments (Figure 5C). There was no
significant change in LV functions (Figure 5D, E).
UCB–derived MNC therapy suppressed the PAB-induced
increase in pathogenic gene expression
Specific cardiac pathogenic markers were used for the
diagnosis of heart failure and recovery. The dysfunc-
tional heart tissue of PAB mice showed an elevated level
of pathogenic gene expression (BNP, ANP, Acta1and
Myh7) compared to a significant reversal of these genes
in the group of animals receiving cell transplantation
(Figure 6A- D). The expression of Myh6 was notrable RV remodeling after pulmonary artery banding. (A) Short-axis
tal groups. Pulmonary artery banding (n = 6) produced severe RV
nimals (n = 6). Four weeks after cell transplantation, there was a
B) Magnetic resonance imaging-derived right ventricular volumes in
ated an increase in RV volume (** P-value <0.005 versus control).
e (P-value <0.005 versus PAB). (C) Right ventricular wall thickness
t increase in RV wall thickness (* P-value <0.05); however, the cell
ckness. (D, E) No significant changes in LV functions were noticed
ry banding; RV, right ventricle; UCB-MNCs, umbilical cord
Figure 6 UCB mononuclear cells suppressed PAB-induced increase in pathogenic gene expression and upregulated cardiac transcription factors.
(A through E) Right ventricular free wall was used for quantitative real-time PCR analysis of cardiac pathogenic markers, such as BNP, ANP, Acta1,
Myh7 and Myh6. Transcript levels of these markers were measured in heart tissue of the PAB-only group and compared with that of the UCB-MNC
transplanted group. (F) Cardiac transcription factors (GATA4, Kdr, Mef2c and Nkx2.5) were significantly upregulated in the UCB-MNC transplanted heart
tissue in comparison with PAB-only heart tissue (n = 4, ** P-value <0.05 versus PAB). Data are expressed as fold change. All data reported are representative
of four independent experiments performed in triplicate and are normalized to those of GAPDH. Data are presented as mean ± SEM. PAB, pulmonary
artery banding; SEM, standard error of the mean; UCB-MNCs, umbilical cord blood-mononuclear cells.
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(Figure 6E). Transcriptional regulation by multiple car-
diac transcription factors, such as GATA4, Kdr, Mef2c,
and Nkx2.5, is associated with an adaptive cardiac re-
generative process [20]. After PAB, the transcript levels
of cardiac progenitors GATA4, Kdr, Mef2c, and Nkx2.5
were significantly lower than those of control tissue.
The embryonic gene expression profile was reversed
upon transplantation of UCB-MNCs (Figure 6F).
UCB-derived MNCs reduce the fibrosis of PAB-induced
ventricular injury and promote proliferation, angiogenesis
Animals were sacrificed after the eight-week follow-up
study and heart tissue was collected for immunofluores-
cence and histopathology. Cardiomyocyte proliferation
in the RV was examined by immunofluorescence using a
Ki-67 antibody. The nuclear protein Ki-67 expression
occurs in all phases of the cell cycle [21]. Images of hearttissue from PAB with cell transplantation revealed an in-
crease in expression of Ki-67 positive cells in the regions
adjacent to fibrosis (Figure 7A, B). Ki-67 expressing cells
increased significantly from 3% ± 1% in the PAB only
group to 13.33% ± 3.05% after UCB-MNCs injection
(P–value <0.005, Figure 7C). H & E staining did not
show any lesions or tumor formation in any of these
animal groups (Figure 7D). Mason-Trichrome stain indi-
cated significant fibrosis formation in the RV area of mice
in response to PAB (Figure 7E). The blue color areas were
analyzed using cellSens dimension software. Animals that
received UCB-MNCs demonstrated minimal fibrosis
(8.75% ± 4.3%) compared to PAB-only animal groups
(29.25% ± 4.34%), with a significant difference (P-value
<0.005) between these two groups (Figure 7F). Thus, the
UCB cell delivery in the setting of PAB demonstrated a
significant reduction in RV fibrosis compared to the
PAB-only group. Immunofluorescence staining revealed
Figure 7 UCB-MNCs transplantation augments myocardial cell proliferation and attenuates myocardial fibrosis. Myocyte proliferation was
assessed by Ki-67 immuno-fluorescence staining in RV of (A) PAB-only and (B) UCB-MNCs treated animals. Ki-67 positive cells were stained green
and nuclei were in blue. The Ki-67 expressions were quantified and data are shown in a bar graph (C). Cell transplantation of UCB-MNCs results in
enhanced cellular proliferations when compared to PAB-only animals (***P–value <0.005 versus PAB; scale bars = 100 μm). The images were
representatives of three PAB-only and three cells treated samples. (D) Representative images of control, PAB and UCB-MNCs transplanted RV
(n = 5 each) stained for hematoxylin and eosin (H & E) for any lesions or tumor formation. (E) Histological sections were stained with Masson-
Trichrome stain (blue) to identify the fibrotic area of RV in response to PAB and cells delivery. Viable myocardial cells was stained red and fibrosis
was blue (scale bars = 50 μm). (F) Percentage circumferential fibrosis measured in short-axis Masson-Trichrome staining was significantly smaller in
UCB-MNCs transplanted heart compared to the PAB-only group (***P–value <0.005 versus PAB and control). PAB, pulmonary artery banding; RV,
right ventricle; UCB-MNCs, umbilical cord blood-mononuclear cells.
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pression in the RV after UCB-MNC transplantation
compared with the PAB-only group of animals. The
small and large blood vessels (endothelial) demon-
strated a significantly higher percentage in the myocar-
dium (Figure 8; P = 0.01) of RV, whereas, the blood
vessel density in the untreated LV demonstrated nodetectable difference between the cells group and the
PAB-only group.
Discussion
UCB offers a prevalent cell source for autologous regen-
erative applications in the setting of in utero diagnosis
such as congenital heart disease. The collection and
Figure 8 Mononuclear cells of UCB paracrine action and vascular reactivity in right ventricle. Immunofluorescence analysis for the angiogenesis
marker CD31 was performed on paraffin embedded cell-treated and PAB only heart tissue. (A-F) Vascularity in RV and LV was assessed, and
resulted in an increase in the number of blood vessels in RV after four weeks of cells delivery (P = 0.01 versus PAB, scale bars = 100 μm). (G, H)
CD31 positive vessels (endothelial-red) were analyzed through CellSens Dimension software (n = 4) and non-specific/background was filtered out
for final calculation. A representative image (LV, RV) of immunofluorescence staining is illustrated. LV, left ventricle; PAB, pulmonary artery banding;
RV, right ventricle; UCB, unbilical cord blood.
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stem cell transplantation with optimization now required
for emerging downstream applications. With a focus on
right ventricular dysfunction due to pressure overload, we
herein empirically tested the safety and efficacy of h-UCB
derived MNCs within an immunodeficient physiological
system. Using real-time monitoring systems, the safety of
the direct intramyocardial injection of h-UCB-derived
MNCs into the RV of a murine model system was deter-
mined in a dose–response study. Furthermore, this study
established the efficacy of UCB-derived MNCs in prevent-
ing maladaptive right ventricular remodeling leading to
end-stage heart failure indicated by biochemical and histo-
logical evidence of disease. Collectively, h-UCB can beprocessed to produce a point-of-care product for intra-
cardiac delivery that has a wide range of safe doses and is
capable of reversing the pathological changes associated
with chronic pressure overload on the RV.
The current study is notable for the rational dose se-
lection of h-UCB-derived MNCs and safe delivery to the
right myocardium. UCB stem cells have been delivered
to the myocardium safely in animals and also have been
used in clinical trials for the treatment of myocardial in-
farction [12,22-24]. The major safety concern of using
stem cells to repair the diseased heart is the occurrence
of arrhythmias and inflammatory tissue damage [25].
The first part of our study was focused on safety assess-
ment and dose selection of UCB cells to be delivered to
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term safety study determined the risk-to-benefit ratio of
UCB-MNCs transplantation to the RV of the mouse
heart using real-time monitoring telemetry systems. This
study demonstrated that the manufactured UCB-derived
product did not show any arrhythmic incidence follow-
ing injection into the RV. Specifically, the UCB-MNCs
did not alter QT or ST-segments or the morphology of
ECG waves after cell implantation at 0.2, 0.4 or 0.8 mil-
lion cells/heart. Notably, ECG showed that all animals
receiving cells maintained a normal rhythm, ventricular
size and function with no evidence of tumor formation.
These results are consistent with previous studies using
bone marrow that reported no incidence of ventricular
arrhythmias and inflammation in humans [26]. Overall,
the cardio-toxicity studies provide evidence that UCB-
MNCs transplantation has a safe therapeutic window up
to 0.4 to 0.8 × 106 cells/heart in normal physiological
systems.
Appropriate heart failure model systems with diseased
myocardium are an important component for advanced
product development of novel regenerative medicine.
Several models have been developed recently for cardiac
complications, such as myocardial infarction, and ad-
dress the heart dysfunctions by using a cell therapy
method. RV remodeling comprises multiple adaptation
mechanisms to increased pressure volume overload,
which in concert determine RV performance as well as
clinical outcome in patients [27]. MRI findings indicate
that a mouse model at four weeks post-PAB has a di-
lated RV chamber with increased pressure load. As the
ventricular contractile weakening progresses, it causes
diminished cardiac output that results in a significant
RV hypertrophic response [28,29]. Similar results were
observed in MRI studies in patients with chronic pres-
sure overload [30,31]. The data attained from the RV
pressure overload are in line with earlier reports
[19,27,32]. In patients with congenital heart disease, the
RV is subjected to abnormal loading conditions and this
dysfunction is a major cause of mortality [33]. These ob-
servations are consistent with our mouse data and sup-
port the physiological relevance of this RV heart failure
model system.
UCB cells have emerged as a viable alternative to other
sources of stem cells and are most widely used in
hematopoietic stem cell therapy [34,35]. UCB is a rich
source of hematopoietic stem/progenitor cells with en-
hanced potency of myogenic differentiation and prolifer-
ative characteristics. In addition, UCB could be used in
clinical settings for cell transplantations [36-38]. To as-
sess the efficacy in a more clinically relevant cardiac
model, UCB-MNCs were delivered into the myocardium
of mice with severe right ventricular failure. We have ex-
amined the data of ventricular performance, remodelingof the heart, pathology and gene expression analysis four
weeks after cell injection. After four weeks, cell injec-
tions to the injured RV showed benefit based on RV
pressure overload, morphology and structural aspects
compared with the PAB-only mice. Imaging analysis
showed an increase in wall thickness and reduced cham-
ber size of RV in the cell group compared to PAB group
animals. Several studies have shown that UCB cell trans-
plantation increased neovascularization and thus im-
proved cardiac function [39,40]. A recent study also
observed that the LV exhibited an improved function
after cell transplantation, suggesting a paracrine effect to
improve cardiac function [41]. The present data demon-
strated that UCB cells are capable of enhancing myocyte
proliferation and improving cardiac function; however,
the underlying mechanisms remain not fully understood.
Our data provide another example of paracrine mechan-
ism of UCB-MNCs that could be coupled with angio-
genesis to contribute towards cardiac repair, supported
by substantial evidence highlighting the importance of
the paracrine effect of stem cells [42]. We demonstrate
here that UCB-MNC injection to the RV after four
weeks of PAB is sufficient to initiate myocardial angio-
genesis. Since we observed an increased endothelial
marker (CD31) expression in the RV after cells injection,
these data suggest that a paracrine mechanism of UCB-
MNC stimulated angiogenesis. These observations dem-
onstrating the paracrine mechanism of UCB cells that
play a role in tissue regeneration and stimulating angio-
genesis were confirmed [43]. The improved heart func-
tions in PAB mice following cell injection suggest that
paracrine effects may be playing a vital role in RV re-
modeling as well.
Beyond the pathophysiology response at the organ
level due to PAB, the cellular response to pressure over-
load in the RV has not been fully elucidated in a murine
model system. The pressure overloaded PAB model and
our pathology data demonstrate that the phenotype re-
capitulates biochemical and cellular changes consistent
with heart failure. In the present study, we measured
specific cardiac gene expression, such as ANP, BNP,
acta-1 and Myh-7, in the RV of a pressure overload mur-
ine model in response to intramyocardial UCB-MNCs
delivery. Significantly higher expression levels of these
sensitive markers seen in the PAB-only group correlate
with the severity and prognosis of heart failure [44,45].
Cell transplantation in the myocardium of banded ani-
mals showed a significant reversal of these cardiac pre-
dictive markers. These results indicate that UCB-MNCs
delivery into the myocardium prevents the over expres-
sion of cardiac hypertrophy markers ANP, BNP, Acta-1
and Myh7 in the RV. The upregulation of Myh7 and
downregulation of Myh6 are common in human heart
disease [46]. The ratios of expression levels of Myh6 and
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beneficial effects on cardiac contractility. Collectively,
these data reveal that UCB-MNCs improve myocardial
energetics in cardiac hypertrophy and preserve the heart
function after RV pressure overload. Previous studies
demonstrate that cardiac progenitors play a vital role in
pathological remodeling of the RV [47,48]. The fibrosis
formation and failing heart phenotype including RV
chamber dilation in the PAB-only group profoundly
blunted the gene expression of GATA-4, kdr, Mef2c and
Nkx2.5. The up-regulation of these cardiac markers may
indicate the stimulation of endogenous cardiac progeni-
tors after cells transplantation in the myocardium. The
endogenous cardiac progenitor stimulation could diminish
pathological remodeling and improve cardiac function.
Cardiac fibrosis is a common feature in patients with
severe cardiac pathology and leads to secondary compli-
cations with disruption of electro-mechanical perform-
ance [49]. The right ventricular pressure overload
hypertrophy in the PAB-only group of mice was accom-
panied by extensive fibrosis in the ventricular wall with a
significant reversal upon treatment with UCB-derived
mononuclear cell therapy. The current study indicates
that UCB-MNCs may have dramatic anti-fibrotic prop-
erties and enhance cardiac repair for normal cardiac
function. A possible explanation for UCB cells to de-
crease fibrosis in the RV wall is correlated with the para-
crine effect and proliferation of endogenous cells in the
heart. The vascular remodeling after cell injection re-
duces collagen content and thus changes the extracellu-
lar matrix. Diminished expression of Ki-67 in PAB-only
animals is in line with results reported in patients with
heart disease due to aortic valve stenosis who have lower
Ki-67 expression [50]. Immunofluorescence images of
UCB-MNC treated RV sections stained with Ki-67 indi-
cated proliferating cells in the fibrotic area with pre-
served myocardial architecture. Although these studies
are limited to a single marker with tissue-based analysis,
these data indicate a powerful response to cell trans-
plantation. Therefore, the paracrine effect of UCB-
derived cell-based therapy may be directly stimulating
endogenous cellular proliferation to avoid fibrotic depos-
ition and pathological changes in the RV. These observa-
tions are consistent with recent reports that in response
to tissue injury, UCB cells can express and secrete para-
crine factors that can activate endogenous repair mech-
anism [51].
Conclusions
Congenital heart disease leads to significant long-term
morbidity due to inherently compromised cardiac struc-
ture and function. Regenerative medicine offers a prom-
ising outlook to rebuild the myocardium if cell-based
therapies can be safely achieved with feasible protocols.Herein, h-UCB-derived MNCs have been collected,
processed, and monitored within a murine model system
for cardiac toxicity. The results indicate that a wide
therapeutic window exists for UCB-derived cells with
direct intramyocardial delivery and the target dose of
0.4 million cells/animal demonstrated reversal of patho-
logical changes in the RV due to pressure overload heart
failure. These results provide the rational design for future
studies applying autologous regenerative strategies for
congenital heart disease limited by right ventricular
performance.
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